Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Humacyte (HUMA) Cash from Operations (2024 - 2025)

Humacyte has reported Cash from Operations over the past 2 years, most recently at 26100000.0 for Q4 2025.

Quarterly results put Cash from Operations at 26100000.0 for Q4 2025, up 1.79% from a year ago — trailing twelve months through Dec 2025 was 105000000.0 (down 7.01% YoY), and the annual figure for FY2025 was 105000000.0, down 7.01%.
Cash from Operations for Q4 2025 was 26100000.0 at Humacyte, down from 23900000.0 in the prior quarter.
Over the last five years, Cash from Operations for HUMA hit a ceiling of 21291000.0 in Q2 2024 and a floor of 28600000.0 in Q1 2025.